Rabeprazole sodium (Habeprazole Sodium) is a 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of stomach ulcers and Zollinger-Ellison syndrome. The drug inhibits H(+)-K(+)-exchanging ATPase which is found in gastric parietal cells.

UNH:0.3 μM (IC50)

Administration of rabeprazole leads to a marked decrease in the viability of MKN-28 cells. Exposure to rabeprazole induces significant apoptosis in AGS cells. Rabeprazole completely inhibits the phosphorylation of ERK 1/2 in the MKN-28 cells, whereas the same effect is not observed in either the KATO III or MKN-45 cells. Rabeprazole is able to efficaciously inhibit the phosphorylation of ERK 1/2 in the gastric cancer cells.Thus, rabeprazole can attenuate the cell viability of human gastric cancer cells through inactivation of the ERK1/2 signaling pathway[2].

Rabeprazole does not appear to exacerbate bone metabolic disorders in gastrectomized rats, but rather ameliorates the TG-induced BMD decrease[1].

Rabeprazole is administrated to three gastric cancer cell lines, KATO III, MKN-28 and MKN-45, at a dosage of 0.2 mM for 16 h. The viability of these cells is determined by a trypan blue exclusion assay.(Only for Reference)